Search results
Showing 1 to 50 of 203 results for myocardial infarction
This quality standard covers preventing further cardiovascular disease after a myocardial infarction (heart attack). It includes assessment and cardiac rehabilitation. It describes high-quality care in priority areas for improvement.
View quality statements for QS99Show all sections
Sections for QS99
- Introduction
- List of quality statements
- Quality statement 1: Assessment of left ventricular function
- Quality statement 2: Referral for cardiac rehabilitation
- Quality statement 3: Communication with primary care
- Quality statement 4: Cardiac rehabilitation – assessment appointment
- Quality statement 5 (developmental): Options for cardiac rehabilitation
- Using the quality standard
Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)
Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.
Evidence-based recommendations on myocardial perfusion scintigraphy for diagnosing and managing angina and myocardial infarction in adults.
This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.
This quality standard covers diagnosing and managing acute coronary syndromes in adults (aged 18 and over). Acute coronary syndromes are medical emergencies that include myocardial infarction (heart attack) and unstable angina (unexpected, severe chest pain). It describes high-quality care in priority areas for improvement.
View quality statements for QS68Show all sections
Sections for QS68
- Introduction
- List of quality statements
- Quality statement 1: Diagnosis of acute myocardial infarction
- Quality statement 2: Risk assessment for adults with NSTEMI or unstable angina
- Quality statement 3: Coronary angiography and PCI within 72 hours for NSTEMI or unstable angina
- Quality statement 4: Coronary angiography and PCI for adults with NSTEMI or unstable angina who are clinically unstable
- Quality statement 5: Level of consciousness and eligibility for coronary angiography and primary PCI
- Quality statement 6: Primary PCI for acute STEMI
Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis (CG95)
This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.
Evidence-based recommendations on using thrombolytic drugs (alteplase [Actilyse], reteplase [Rapilysin], streptokinase [Streptase] and tenecteplase [Metalyse]) for treating acute myocardial infarction in adults.
Re-engineering the Post-Myocardial Infarction Medicines Optimisation Pathway
appraisals, to reduce the burden of coronary heart disease (CHD) and Myocardial Infarction (MI), many patients with CHD are...
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)
Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention for treating acute coronary syndromes in adults.
patients who complete a cardiac rehabilitation programme after a myocardial infarction. The aim was to increase the proportion of...
patients who complete a cardiac rehabilitation programme after a myocardial infarction. The aim was to increase the proportion of...
This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.
High-sensitivity troponin tests for the early rule out of NSTEMI (DG40)
Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction)
troponin T testing to aid in the confirmation or exclusion of acute myocardial infarction. Pressure from the commissioners to reduce...
Ticagrelor for the treatment of acute coronary syndromes (TA236)
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.
Myocardial infarction, stroke and stage 5 chronic kidney disease in people with diabetes
Myocardial infarction, stroke and stage 5 chronic kidney disease in people with diabetes Subject(s): Diabetes, Kidney conditions
Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.
patients with acute myocardial infarction who were discharged on dual antiplatelet therapy Subject(s): Myocardial...
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.
ST-segment elevation myocardial infarction (STEMI) who had coronary reperfusion therapy Subject(s): Myocardial infarction
The proportion of patients with acute myocardial infarction with measurement of left ventricular ejection fraction before discharge
Admission rates due to myocardial infarction in people with diabetes
Admission rates due to myocardial infarction in people with diabetes Subject(s): Diabetes Date of publication: 01
Empagliflozin for preventing cardiovascular events after acute myocardial infarction ID6240
In development [GID-TA11265] Expected publication date: TBC
Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making
help and balloon inflation for patients with ST segment elevation myocardial infarction (STEMI) undergoing reperfusion by primary...
The proportion of patients with ST-segment elevation myocardial infarction (STEMI) who had balloon inflation for primary percutaneous...
coronary syndromes (ACS) that is, people: • with ST-segment-elevation myocardial infarction (STEMI) – defined as ST elevation or new...
Implanting a baroreceptor stimulation device for resistant hypertension
In development [GID-IP1180] Expected publication date: TBC
The percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with...
The percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an...
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
View recommendations for TA275Show all sections
Evidence-based recommendations on using coronary artery stents in adults.
Find out about the progress made by the health and care system in implementing NICE guidance on cardiovascular disease management
1-hour protocol using high sensitivity troponin assay to assess acute myocardial infarction (AMI) in patients presenting with chest...
testing against sequential cardiac troponin testing for ruling out myocardial infarction. Any explanatory notes(if applicable) Research...
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
Bioresorbable stent implantation to treat coronary artery disease (IPG732)
Evidence-based recommendations on bioresorbable stent implantation to treat coronary artery disease in adults. This involves implanting a stent (small tube) into a narrowed artery to widen it.
View recommendations for IPG732Show all sections
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)
NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)
NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system
MiraQ for assessing graft flow during coronary artery bypass graft surgery (MTG8)
Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery.
Drug-eluting stents for the treatment of coronary artery disease (TA152)
Evidence-based recommendations on using drug-eluting stents in adults.
Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome (MIB223)
NICE has developed a medtech innovation briefing (MIB) on Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome .
HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (MTG32)
Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography.
Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG494)
Evidence-based recommendations on endoscopic saphenous vein harvest for coronary artery bypass grafting. This involves removing the vein under endoscopic guidance through a small cut near the knee (keyhole surgery).
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
Evidence-based recommendations on off-pump coronary artery bypass grafting. This involves attaching a healthy blood vessel to the heart muscle so that blood can get round (‘bypass’) the affected part of the coronary artery.
View recommendations for IPG377Show all sections
Sections for IPG377
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.